ARCHIVES

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

This article is from The Cancer Letter archive.

Vol. 34 No. 1 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

August 19, 1994

Hamburg Confirmed As FDA Commissioner

May 22, 2009

In Brief: Hong, Posner Awarded ACS Research Professorships; Hawaii Wins Center Grants

July 26, 1996

Von Eschenbach Takes NCI’s Helm As Bush Proposes Budget Increase.

February 8, 2002

Study Finds 4-20% Of Those With HTLV-3 Develop AIDs Within 32 Months Or Less

August 2, 1985

DFA Proposes Controversial Guidelines For Clinical Tests

November 21, 1975